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One-Stage or Multistage PCI in NSTEMI Patients
With Multivessel Disease*José P.S. Henriques, MD, PHD, Bimmer E. Claessen, MD, PHDT here is an ongoing debate about the role ofcoronary revascularization in the settingof non–ST-segment elevation myocardial
infarction (NSTEMI). American and European guide-
lines currently agree that an early invasive strategy
is recommended in patients with at least 1 high-risk
criterion (1,2). However, the optimal treatment strat-
egy for patients with multivessel disease is still
unclear. Multivessel disease occurs frequently: it is
encountered in approximately 50% of patients with
NSTEMI undergoing coronary angiography (3,4).
Treatment options include percutaneous coronary
intervention (PCI) or coronary artery bypass graft sur-
gery. In coronary artery bypass graft, complete revas-
cularization is the gold standard, but in PCI, 2
important unanswered questions remain: 1) Is com-
plete revascularization superior to culprit lesion-
only revascularization? 2) If a percutaneous complete
revascularization strategy is chosen, should all
lesions be treated in a single session, or should the
culprit lesion be treated ﬁrst, and the residual lesions
then be treated in a staged procedure?SEE PAGE 264In this issue of the Journal, the SMILE (Impact of
Different Treatment in Multivessel Non ST Eleva-
tion Myocardial Infarction [NSTEMI] Patients) trial
provides insight into some of these outstanding
issues (5). In this trial of patients with NSTEMI with
multivessel disease, all participants underwent*Editorials published in the Journal of the American College of Cardiology
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information is provided on the beneﬁts or harms
of culprit lesion-only revascularization compared
with complete revascularization. Unfortunately, the
investigators did not report how multivessel disease
was deﬁned (e.g., >50% or >70% diameter stenosis),
and functional testing of intermediate lesions with
fractional ﬂow reserve measurements was not
routinely performed. Patients were randomized in a
1:1 fashion to complete revascularization during a
single procedure or to culprit-only revascularization,
followed by revascularization of the remaining
lesions during the index hospitalization after a mean
interval of 4.76  1.23 days. The investigators used
the radial approach and current-generation drug-
eluting stents in both groups.
The results were surprising, with signiﬁcantly
lower rates of the primary endpoint of major adverse
cardiovascular and cerebrovascular events (deﬁned
as cardiac death, death, reinfarction, rehospitaliza-
tion for unstable angina, repeat coronary revascular-
ization, and stroke) in the 1-stage group at 1-year
follow-up. This difference was entirely caused by a
higher rate of target vessel revascularization (TVR) in
the multistage group. This ﬁnding deserves further
investigation, because the TVR rate (15.4% at 1 year)
in the multistage group was unprecedentedly high in
the era of current-generation drug-eluting stents. The
only study that comes close to this high event rate is
the SYNTAX (Synergy between PCI with TAXUS and
Cardiac Surgery) trial, where the 1-year repeat revas-
cularization rate (including TVR, but also non-TVR)
was 13.5% in the PCI arm (6). However, in SYNTAX,
the mean SYNTAX score was 28, compared with 15 in
the current study, and obsolete ﬁrst-generation
paclitaxel-eluting stents were used (7).
Moreover, in SMILE, there were no differences
between groups in terms of well-known predictors of
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274in-stent restenosis, such as diabetes mellitus, number
of vessels treated, lesion length, reference vessel
diameter, and so on (8). The event rates start to
diverge after 6 months, which is hard to explain when
the only difference between the groups was the
timing of PCI on nonculprit lesions. To better under-
stand this ﬁnding, more information is needed about
the type of repeat revascularization. The article only
mentions the number of vessels treated, but no
information is provided on the number of lesions
treated. The SMILE investigators only reported TVR;
therefore, it is unclear if the repeat revascularization
was for in-stent restenosis (target lesion revasculari-
zation) or for a new lesion (non-target-lesion revas-
cularization). Furthermore, no data are provided on
the use of invasive or noninvasive testing for
ischemia in patients undergoing TVR. The results are
counterintuitive, because there is a higher TVR rate in
patients whose anatomy is known, where one can
plan which lesions to treat in advance and can treat
them electively during routine duty hours, rather
than in an emergency setting and frequently during
off-hours. Until more information is provided to
substantiate this ﬁnding, it may be best to discard it
as an outlier caused by chance.
There were no differences in terms of hard clinical
endpoints, such as death and myocardial infarction,between the 2 groups. However, the trial was not
sufﬁciently powered to detect potential differences in
mortality between the 2 strategies. The single-stage
approach was associated with increased use of
contrast medium during the initial procedure (me-
dian, 295 ml vs. 180 ml; p < 0.001), but this did not
result in higher serum creatinine levels at 48 h after
the index procedure or before discharge. It should be
noted that patients with an estimated glomerular
ﬁltration rate <60 ml/min/m2 were excluded from
the study. Because of the risks associated with
contrast medium use in patients with chronic kidney
failure, a staged approach may be preferable in these
patients.
In conclusion, when interpreting SMILE, one may
ﬁnd a reason to frown. Many questions remain about
the treatment of multivessel disease in patients un-
dergoing PCI for NSTEMI. The unexpected and
unexplained ﬁnding of increased TVR with multi-
stage complete revascularization deserves further
attention.
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